Related Experiment Video
Updated: May 7, 2026
Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
Published on: February 8, 2017
Clinical impact following the establishment of a specialized brain metastases tumor board
Izaskun Valduvieco1,2, Gabriela Antelo1, Alberto Di Somma3,4,5
1Radiation Oncology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Purpose:
To evaluate the impact of brain metastasis tumor board (BMTB) on treatment patterns and survival.
Methods:
365 patients with brain metastases (BM) were analyzed at the Hospital Clínic de Barcelona from October 2019 to October 2022. This included those treated in the department of neurosurgery and radiation oncology during the first 18 months following its establishment. Demographic, clinicopathological, and treatment data were recorded and compared between the groups with and without BTBM.
Results:
Of 365, 95 were in the BMTB group and 270 in the non-BMTB group. Patients discussed at the BMTB had higher rates of surgery (53.7% vs. 14.7%, p < 0.001) and stereotactic radiosurgery (63.1% vs. 21.6%, p < 0.001). The time between surgical treatment and adjuvant radiotherapy was shorter in the BMTB group (37 days, 95% CI 4 vs. 48 days, 95% CI 18, p = 0.018). No differences were observed in local progression (26.0% vs. 20.8%, p = 0.9) but there were differences in cerebral progression (43.2% vs. 27.4%, p = 0.004). Rescue treatment was more common in the BMTB group (26.3% vs 10.0%, p < 0.001). Median survival after BM was significantly longer in the BMTB group (28.2 ± 2.7 vs. 12.7 ± 1.04 months, p < 0.001).
Conclusion:
Multidisciplinary discussions for patients with BM are crucial as they improve overall survival through integrated therapies. Additional trials are needed to optimize treatment integration in this complication.
